165 related articles for article (PubMed ID: 24000042)
1. Utilization of intravenous bisphosphonates in patients with bone metastases secondary to breast, lung, or prostate cancer.
Hagiwara M; Delea TE; Cong Z; Chung K
Support Care Cancer; 2014 Jan; 22(1):103-13. PubMed ID: 24000042
[TBL] [Abstract][Full Text] [Related]
2. Use of intravenous bisphosphonates in patients with breast, lung, or prostate cancer and metastases to bone: a 15-year study in two large US health systems.
Oster G; Lamerato L; Glass AG; Richert-Boe KE; Lopez A; Chung K; Richhariya A; Dodge T; Wolff GG; Balakumaran A; Edelsberg J
Support Care Cancer; 2014 May; 22(5):1363-73. PubMed ID: 24389827
[TBL] [Abstract][Full Text] [Related]
3. Real-world use of denosumab and bisphosphonates in patients with solid tumours and bone metastases in Germany.
Diel I; Ansorge S; Hohmann D; Giannopoulou C; Niepel D; Intorcia M
Support Care Cancer; 2020 Nov; 28(11):5223-5233. PubMed ID: 32086567
[TBL] [Abstract][Full Text] [Related]
4. Natural history of skeletal-related events in patients with breast, lung, or prostate cancer and metastases to bone: a 15-year study in two large US health systems.
Oster G; Lamerato L; Glass AG; Richert-Boe KE; Lopez A; Chung K; Richhariya A; Dodge T; Wolff GG; Balakumaran A; Edelsberg J
Support Care Cancer; 2013 Dec; 21(12):3279-86. PubMed ID: 23884473
[TBL] [Abstract][Full Text] [Related]
5. Denosumab treatment of prostate cancer with bone metastases and increased urine N-telopeptide levels after therapy with intravenous bisphosphonates: results of a randomized phase II trial.
Fizazi K; Bosserman L; Gao G; Skacel T; Markus R
J Urol; 2013 Jan; 189(1 Suppl):S51-7; discussion S57-8. PubMed ID: 23234632
[TBL] [Abstract][Full Text] [Related]
6. Bisphosphonates and other bone agents for breast cancer.
Wong MH; Stockler MR; Pavlakis N
Cochrane Database Syst Rev; 2012 Feb; (2):CD003474. PubMed ID: 22336790
[TBL] [Abstract][Full Text] [Related]
7. Denosumab treatment of prostate cancer with bone metastases and increased urine N-telopeptide levels after therapy with intravenous bisphosphonates: results of a randomized phase II trial.
Fizazi K; Bosserman L; Gao G; Skacel T; Markus R
J Urol; 2009 Aug; 182(2):509-15; discussion 515-6. PubMed ID: 19524963
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness of denosumab vs zoledronic acid for prevention of skeletal-related events in patients with solid tumors and bone metastases in the United States.
Stopeck A; Rader M; Henry D; Danese M; Halperin M; Cong Z; Qian Y; Dansey R; Chung K
J Med Econ; 2012; 15(4):712-23. PubMed ID: 22409231
[TBL] [Abstract][Full Text] [Related]
9. Gender differences in persistency to bisphosphonates in patients with metastatic breast and prostate cancer.
Hadji P; Kyvernitakis J; Albert U; Jockwig J; Kostev K
Int J Clin Pharmacol Ther; 2014 May; 52(5):352-9. PubMed ID: 24691062
[TBL] [Abstract][Full Text] [Related]
10. Safety of long-term denosumab therapy: results from the open label extension phase of two phase 3 studies in patients with metastatic breast and prostate cancer.
Stopeck AT; Fizazi K; Body JJ; Brown JE; Carducci M; Diel I; Fujiwara Y; Martín M; Paterson A; Tonkin K; Shore N; Sieber P; Kueppers F; Karsh L; Yardley D; Wang H; Maniar T; Arellano J; Braun A
Support Care Cancer; 2016 Jan; 24(1):447-455. PubMed ID: 26335402
[TBL] [Abstract][Full Text] [Related]
11. Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates.
Fizazi K; Lipton A; Mariette X; Body JJ; Rahim Y; Gralow JR; Gao G; Wu L; Sohn W; Jun S
J Clin Oncol; 2009 Apr; 27(10):1564-71. PubMed ID: 19237632
[TBL] [Abstract][Full Text] [Related]
12. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study.
Fizazi K; Carducci M; Smith M; Damião R; Brown J; Karsh L; Milecki P; Shore N; Rader M; Wang H; Jiang Q; Tadros S; Dansey R; Goessl C
Lancet; 2011 Mar; 377(9768):813-22. PubMed ID: 21353695
[TBL] [Abstract][Full Text] [Related]
13. Zoledronic acid: a pharmacoeconomic review of its use in the management of bone metastases.
McKeage K; Plosker GL
Pharmacoeconomics; 2008; 26(3):251-68. PubMed ID: 18282018
[TBL] [Abstract][Full Text] [Related]
14. Bisphosphonates for breast cancer.
Pavlakis N; Schmidt R; Stockler M
Cochrane Database Syst Rev; 2005 Jul; (3):CD003474. PubMed ID: 16034900
[TBL] [Abstract][Full Text] [Related]
15. Management of bone health in solid tumours: From bisphosphonates to a monoclonal antibody.
von Moos R; Costa L; Gonzalez-Suarez E; Terpos E; Niepel D; Body JJ
Cancer Treat Rev; 2019 Jun; 76():57-67. PubMed ID: 31136850
[TBL] [Abstract][Full Text] [Related]
16. Extended use of intravenous bisphosphonate therapy for the prevention of skeletal complications in patients with cancer.
Crawford BS; McNulty RM; Kraut EH; Turowski RC
Cancer Invest; 2009 Dec; 27(10):984-8. PubMed ID: 19909013
[TBL] [Abstract][Full Text] [Related]
17. Risk Factors for Developing Skeletal-Related Events in Breast Cancer Patients With Bone Metastases Undergoing Treatment With Bone-Modifying Agents.
Tanaka R; Yonemori K; Hirakawa A; Kinoshita F; Takahashi N; Hashimoto J; Kodaira M; Yamamoto H; Yunokawa M; Shimizu C; Fujimoto M; Fujiwara Y; Tamura K
Oncologist; 2016 Apr; 21(4):508-13. PubMed ID: 26975863
[TBL] [Abstract][Full Text] [Related]
18. Examination of burden of skeletal-related events in patients naive to denosumab and intravenous bisphosphonate therapy in bone metastases from solid tumors population.
Bhowmik D; Song X; Intorcia M; Gray S; Shi N
Curr Med Res Opin; 2019 Mar; 35(3):513-523. PubMed ID: 30286662
[TBL] [Abstract][Full Text] [Related]
19. Incidence of osteonecrosis of the jaw in patients with bone metastases treated sequentially with bisphosphonates and denosumab.
Loyson T; Van Cann T; Schöffski P; Clement PM; Bechter O; Spriet I; Coropciuc R; Politis C; Vandeweyer RO; Schoenaers J; Dumez H; Berteloot P; Neven P; Nackaerts K; Woei-A-Jin FJSH; Punie K; Wildiers H; Beuselinck B
Acta Clin Belg; 2018 Apr; 73(2):100-109. PubMed ID: 28693379
[TBL] [Abstract][Full Text] [Related]
20. Toxicities following treatment with bisphosphonates and receptor activator of nuclear factor-κB ligand inhibitors in patients with advanced prostate cancer.
Gartrell BA; Coleman RE; Fizazi K; Miller K; Saad F; Sternberg CN; Galsky MD
Eur Urol; 2014 Feb; 65(2):278-86. PubMed ID: 23706567
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]